A biopharmaceutical company focused on fighting cancer, Verastem makes AVMAPKI FAKZYNJA CO-PACK (avutometinib/defactinib), a treatment for a rare form of ovarian cancer called low-grade serous ovarian cancer that received accelerated FDA approval in 2025. It's also developing VS-7375, an oral drug aimed at tumors driven by a common KRAS mutation. Based in the US, the company concentrates on the RAS/MAPK pathway, a key driver in many cancers.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -25.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.